First Light Asset Management LLC Has $9.45 Million Holdings in Guardant Health, Inc. (NASDAQ:GH)

First Light Asset Management LLC lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 52.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 309,389 shares of the company's stock after selling 339,604 shares during the quarter. First Light Asset Management LLC owned about 0.25% of Guardant Health worth $9,452,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Guardant Health during the 4th quarter valued at about $36,438,000. Lord Abbett & CO. LLC bought a new position in Guardant Health in the third quarter valued at approximately $15,624,000. Vanguard Group Inc. boosted its holdings in shares of Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares during the period. Eversept Partners LP bought a new stake in shares of Guardant Health during the fourth quarter worth $8,433,000. Finally, Blue Water Life Science Advisors LP lifted its position in Guardant Health by 53.9% in the 4th quarter. Blue Water Life Science Advisors LP now owns 694,047 shares of the company's stock valued at $21,203,000 after acquiring an additional 243,000 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GH. Canaccord Genuity Group increased their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday. The Goldman Sachs Group lifted their target price on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Scotiabank raised their target price on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Finally, Piper Sandler upped their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Twenty-one equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Guardant Health currently has an average rating of "Buy" and a consensus target price of $51.64.

Guardant Health Trading Up 3.5 %

GH traded up $1.64 on Thursday, reaching $48.87. The stock had a trading volume of 5,049,663 shares, compared to its average volume of 2,171,994. The firm has a 50-day moving average of $43.61 and a 200-day moving average of $37.94. Guardant Health, Inc. has a fifty-two week low of $17.99 and a fifty-two week high of $52.99. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of -13.73 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.